Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.
about
Orexin receptors: pharmacology and therapeutic opportunitiesPhysiology of the orexinergic/hypocretinergic system: a revisit in 2012Orexin antagonists for neuropsychiatric disease: progress and potential pitfallsThe dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administrationThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsToward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers.[The newer sedative-hypnotics].The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold.A food restriction protocol that increases drug reward decreases tropomyosin receptor kinase B in the ventral tegmental area, with no effect on brain-derived neurotrophic factor or tropomyosin receptor kinase B protein levels in dopaminergic forebraThe importance of the 6- and 7-positions of tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats.The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking.The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.The role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship.Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsyRadiosynthesis and evaluation of [11C]EMPA as a potential PET tracer for orexin 2 receptors.Orexin Receptor Targets for Anti-Relapse Medication Development in Drug Addiction.The use of the reinstatement model to study relapse to palatable food seeking during dieting.Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders.The hypocretin/orexin system: an increasingly important role in neuropsychiatry.Orexin receptor antagonists--a patent review (2010 to August 2014).Orexin OX2 Receptor Antagonists as Sleep Aids.Morphological and Physiological Interactions Between GnRH3 and Hypocretin/Orexin Neuronal Systems in Zebrafish (Danio rerio).Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands.Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors.Distinct effects of IPSU and suvorexant on mouse sleep architecture.Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats.Orexin and Central Modulation of Cardiovascular and Respiratory Function.Both Ox1R and Ox2R orexin receptors contribute to the cardiorespiratory response evoked from the perifornical hypothalamus.The osmotically and histamine-induced enhancement of the plasma vasopressin level is diminished by intracerebroventricularly administered orexin in rats.Expression and role of receptor 1 for orexins in seminiferous tubules of rat testis.Optogenetic identification of hypothalamic orexin neuron projections to paraventricular spinally projecting neurons.Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement.
P2860
Q24597418-6FAF689D-F62D-419C-BED0-12B081625D38Q26822470-EEF15FD6-21AE-4174-B97B-933F5029E3B4Q26852653-1C32B41F-3CBE-4BB7-BCA6-5923878AF803Q28483933-31304E55-ECCF-4CD6-9384-73666F4EB228Q30486707-14EEB22B-7917-467D-993A-90C2AE939527Q33768567-52338E8A-24D0-4CC1-8306-714BB9B25CD6Q34143490-4A6A27C4-4B35-4D4A-9A5D-EE6AAC535C3FQ34975026-5E415F93-3698-4C89-8268-2E62974CC229Q35534373-A420E706-2E36-439A-967F-2C58C93A24B2Q36011454-0B9FBCEC-A6CC-4A65-BA86-0577CC6FB52FQ36100315-DDF04EAE-2032-407A-9E75-973B994C91C2Q36309147-C7D8C86B-AE39-448A-AAE8-9C668A410F13Q36375246-78273E17-4E5F-45D5-ABA8-F06E1EE7A109Q36417619-19DE9B42-E920-4403-ACF5-449E84BD2A1CQ36608029-F74AEE30-43B7-47B5-9E19-C66EFCD842AEQ36878958-6049019C-3A9F-4463-A74B-B7F58A23D090Q37128655-389172AE-61E2-455C-8C1C-2CCC18A86EF7Q37203397-55216B40-1728-4AA5-8481-734719172B93Q38108972-C895D377-9050-4560-8B79-F4EE139EA5E6Q38231949-70DB24F3-39A8-4595-A11F-AC0133954746Q38269308-A3C21E47-3F32-4F46-8EBA-04620197E7C9Q39026714-A37E726F-F731-4817-877B-D528B8165645Q39481582-C5E38A25-260F-466B-B639-D996DAD4D156Q39617477-74C973D9-B035-4952-ABBF-49F84149F7B5Q41895360-9CE2D130-5559-46CF-8B55-0BE19CB201BAQ41998350-044A3ED4-C889-49E7-BCD6-E99E32D227BAQ42825760-72D00563-6AC2-4747-89BD-C09B50689241Q46072560-BD84C4B4-CC0D-4F5B-8C7B-4870423DAEAAQ47357997-34AD7538-A709-4A1A-9C5A-66D0FB489A53Q47675929-128930B0-FCEB-4C74-A4BE-A892B5F02B8EQ48185212-57DBE726-1F9C-4384-823A-F508B566E9FFQ48252113-E76A0E2A-0DBE-49F7-B15C-B2F192DC6E75Q48325029-12ACFA30-5947-4E95-85E1-CFEBC16182D7Q51892779-9CC55161-7A5F-4DB2-8972-DA83408E25A6
P2860
Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Biochemical and electrophysiol ...... ctive OX1 and OX2 antagonists.
@ast
Biochemical and electrophysiol ...... ctive OX1 and OX2 antagonists.
@en
Biochemical and electrophysiol ...... ctive OX1 and OX2 antagonists.
@nl
type
label
Biochemical and electrophysiol ...... ctive OX1 and OX2 antagonists.
@ast
Biochemical and electrophysiol ...... ctive OX1 and OX2 antagonists.
@en
Biochemical and electrophysiol ...... ctive OX1 and OX2 antagonists.
@nl
prefLabel
Biochemical and electrophysiol ...... ctive OX1 and OX2 antagonists.
@ast
Biochemical and electrophysiol ...... ctive OX1 and OX2 antagonists.
@en
Biochemical and electrophysiol ...... ctive OX1 and OX2 antagonists.
@nl
P2093
P356
P1476
Biochemical and electrophysiol ...... ctive OX1 and OX2 antagonists.
@en
P2093
Edilio Borroni
Emmanuel Pinard
Frédéric Knoflach
Joseph G Wettstein
Pari Malherbe
P304
P356
10.1124/MOL.109.055152
P577
2009-06-19T00:00:00Z